Drugs / IMC-002
Trials 5
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT05946226 | Sep 2023 → Dec 2025 | digestive system neoplasm | Suzhou Immunofoco Biotechnology Co., Ltd | Unknown | No outcome recorded |
| Phase 1 | NCT05276310 | Jun 2022 → Dec 2027 expected | — | ImmuneOncia Therapeutics Inc. | Recruiting | No outcome recorded |
| Phase 1 | NCT04306224 | Jun 2020 → Oct 2022 | cancer, lymphoma | ImmuneOncia Therapeutics Inc. | Completed | No outcome recorded |
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT06535412 | Oct 2024 → Dec 2028 expected | systemic lupus erythematosus | ImmuneCare Biopharmaceuticals (Shanghai) Co., Ltd. | Recruiting | No outcome recorded |
| Phase 1/2 | NCT06557174 | Oct 2024 → Nov 2025 overdue | neuromyelitis optica | ImmuneCare Biopharmaceuticals (Shanghai) Co., Ltd. | Not yet recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 10
| Date | Issuer | Release |
|---|---|---|
| 2026-10-10 | ImmuneOnco Biopharmaceuticals (Shanghai) Inc. | Results 宜明昂科将于ACR 2026公布IMM0306治疗系统性红斑狼疮的Ib/II期最新临床研究成果 immuneonco.com ↗
其中，R/R MZL队列ORR达92.3%，CRR达53.8%；R/R FL队列ORR达88.6%，CRR达70.5%，且未观察到细胞因子释放综合征（CRS）相关毒性。 |
| 2026-06-04 | ImmuneOnco Biopharmaceuticals (Shanghai) Inc. | Results EULAR 2026 | 宜明昂科以壁报形式公布IMC-002（IMM0306）治疗中重度SLE Ib/II期初步数据，展现“强效与安全”双重突破 immuneonco.com ↗
数据显示，IMC-002在实现深度B细胞清除的同时，展现出优异的安全性与耐受性，且临床疗效强劲持久。 |
| 2025-12-15 | ImmuneOnco Biopharmaceuticals (Shanghai) Inc. | Results 宜明昂科注射用IMC-002(IMM0306)治疗活动性系统性红斑狼疮 lb/II期临床研究中期研究者会在北京顺利召开 immuneonco.com ↗
疗效方面，24周SRI-4应答率优异：0.8mg/kg组达71.4%（5/7），1.2mg/kg组达80%（4/5）。 |
| 2025-12-09 | ImmuneOncia Therapeutics Inc. | Results [기업탐방] 이뮨온시아, "실패 극복" 'CD47 병용' 임상개발 전략은? immuneoncia.com ↗
그 시작점으로 이뮨온시아는 올해 미국 임상종양학회(ASCO 2025)에서 IMC-002의 용량확장(dose extension) 임상1b상에서 첫 적응증으로 진행성 간암(HCC)에서 기존 치료제인 TKI ‘렌바티닙(lenvatinib)’과 병용투여했을 때 전체반응률(ORR) 30%(3/10명)라는 초기 결과를 발표했다. |
| 2025-11-06 | ImmuneOncia Therapeutics Inc. | Results 이뮨온시아, 국제학술지 CRT IMC-002 임상 1상 결과 논문 발표 immuneoncia.com ↗
질병통제율 (DCR) 은 50.0%, 임상적 이득율 (CBR) 은 33.3% 로 나타났다 . |
| 2025-10-31 | ImmuneOnco Biopharmaceuticals (Shanghai) Inc. | Results 宜明昂科阿沐瑞芙普α（IMM0306）治疗系统性红斑狼疮Ib/II期研究在ACR 2025年会公布积极进展 immuneonco.com ↗
在24周时，接受0.8mg/kg剂量的患者中，71.4%（5/7）达到了SRI-4应答；接受1.2mg/kg剂量的患者中，80.0%（4/5）达到了SRI-4 应答， 显示出良好的治疗效果。 |
| 2025-10-20 | ImmuneOncia Therapeutics Inc. | Results 유럽임상종양학회(ESMO) 항암신약 2종 임상결과 발표 immuneoncia.com ↗
차세대 CD47 항체 IMC-002 의 전임상 및 1a/1b 상 임상 결과를 통해 탁월한 안전성과 구조적 차별성을 입증했다 . |
| 2024-06-19 | ImmuneOnco Biopharmaceuticals (Shanghai) Inc. | Regulatory 宜明凯尔IMC-002针对系统性红斑狼疮(SLE)的临床研究申请获得国家药品监督管理局 (NMPA) 批准 immuneonco.com ↗
非常高兴我们的IMC-002针对系统性红斑狼疮(SLE)的临床研究申请(IND)获得国家药品监督管理局(NMPA)批准。 |
| 2022-01-12 | 3D Medicines (Sichuan) Co., Ltd. | Regulatory 思路迪医药 CD47 抗体新药 3D197 临床试验申请获 NMPA 批准 3d-medicines.com ↗
2022年1月7日，思路迪医药（3D Medicines Inc.，简称“思路迪医药”）宣布其第8个临床阶段候选药物3D197注射液临床试验获得中国国家药品监督管理局（NMPA）临床试验批准通知书。 |
| 2021-11-03 | 3D Medicines (Sichuan) Co., Ltd. | Regulatory 思路迪医药 CD47 抗体新药 3D197 临床试验申请获受理 3d-medicines.com ↗
2021年11月3日，思路迪医药（3D Medicines Inc.，简称“思路迪医药”）宣布其第8个临床阶段候选药物3D197注射液临床试验申请获得中国国家药品监督管理局（NMPA）受理。 |
All press releases naming this drug 10 releases
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | IMC-002 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06557174 ↗ |
| Action | Inhibit | “IMC-002 blocks the interaction between CD47 and SIRPα.” NCT04306224 ↗ |
| Route | Intravenous | “intravenous IMC-002” NCT06535412 ↗ |